The EC and EMA have updated a Q&A, first published in May 2017, on the implications of Brexit on drug products. The updated version indicates that “the transfer of the marketing authorization [to the EU] must be fully completed and implemented by the marketing authorization holder before 30 March 2019.”
[/membership][membership level=”0,4″][The content continues for paid members only.]
Login or Subscribe [/membership][membership level=”1,5,6,7,8,9,10,11,12″][membership]
